NovoCure Ltd
Close on Oct 19, 2026
- Market cap
- $1.73B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Oct 29, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Jul 23, 2026 | Before market open | $183.60M | $-0.13 | – |
| Q1 FY2026 Ended Mar 31, 2026 | Apr 30, 2026 | Before market open | $174.10M | $-0.62 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 26, 2026 | Before market open | $174.40M | $-0.22 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Oct 30, 2025 | Before market open | $167.20M | $-0.33 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Jul 24, 2025 | Before market open | $158.80M | $-0.36 | – |
| Q1 FY2025 Ended Mar 31, 2025 | Apr 24, 2025 | Before market open | $155.00M | $-0.31 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 27, 2025 | Before market open | $161.30M | $-0.61 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Oct 30, 2024 | Before market open | $155.10M | $-0.28 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Jul 25, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 2, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 22, 2024 | Before market open | – | – | – |
Company guidance
Outlook given with results on Jul 23, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Adjusted EBITDA*non-GAAP | full year 2026 | $0 to $15.00M | Raised |
| Total net revenue | full year 2026 | $710.00M to $725.00M | Raised |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements NovoCure filed with the SEC
Novocure’s Optune Pax® Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic Cancer
Regulation FD disclosure · EX-99.1 to Form 8-K
Novocure Reports Second Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Novocure’s Optune Pax® Receives CE Mark for the Treatment of Locally Advanced Pancreatic Cancer
Regulation FD disclosure · EX-99.1 to Form 8-K
Novocure Announces Topline Data from the Phase 3 TRIDENT Trial Evaluating Earlier Use of Tumor Treating Fields Therapy in Newly Diagnosed Glioblastoma
Regulation FD disclosure · EX-99.1 to Form 8-K
Novocure Reports First Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer
Regulation FD disclosure · EX-99.1 to Form 8-K
Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update
Results of operations · EX-99.1 to Form 8-K
FDA Approves Novocure’s Optune Pax® for the Treatment of Locally Advanced Pancreatic Cancer
Regulation FD disclosure · EX-99.1 to Form 8-K
Novocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company Update
Results of operations · EX-99.1 to Form 8-K
Novocure Appoints Company President Frank Leonard as Chief Executive Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Novocure Reports Third Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Novocure’s Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC)
Regulation FD disclosure · EX-99.1 to Form 8-K
Novocure Reports Second Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Results From the Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting
Regulation FD disclosure · EX-99.1 to Form 8-K
PRESENTED BY: © 2025 Novocure GmbH. All rights reserved. Novocure is a trademark of Novocure GmbH. MED-GL-PANC-2500004_V2. 20 Appendix Dr Vincent Picozzi
Regulation FD disclosure · EX-99.2 to Form 8-K
[Confidential] © 2025 Novocure GmbH© 2025 Novocure GmbH 1 PANOVA-3 Investor Event May 31, 2025 – Chicago Exhibit 99.3
Regulation FD disclosure · EX-99.3 to Form 8-K
Novocure Reports First Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Novocure’s Optune Lua® Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer
Regulation FD disclosure · EX-99.1 to Form 8-K
Novocure Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update
Results of operations · EX-99.1 to Form 8-K
Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update
Results of operations · EX-99.1 to Form 8-K
Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer
Regulation FD disclosure · EX-99.1 to Form 8-K
Novocure Reports Third Quarter 2024 Financial Results
Results of operations · Executive or director change · EX-99.1 to Form 8-K
Novocure Appoints Christoph Brackmann as Chief Financial Officer
Results of operations · Executive or director change · EX-99.2 to Form 8-K
FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer
Regulation FD disclosure · EX-99.1 to Form 8-K
Novocure Announces Planned CEO Transition
Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Novocure Reports Second Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Novocure Reports First Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
Results of operations · EX-99.1 to Form 8-K
Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer
Regulation FD disclosure · EX-99.1 to Form 8-K
Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma
Regulation FD disclosure · EX-99.1 to Form 8-K
Novocure Announces Preliminary Full Year and Fourth Quarter 2023 Net Revenues and Provides Company Update
Results of operations · EX-99.1 to Form 8-K
Novocure Appoints Dr. Nicolas Leupin as Chief Medical Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-term Growth Drivers and an Accelerated Path to Profitability
Regulation FD disclosure · EX-99.1 to Form 8-K
Novocure Reports Third Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Novocure Provides Update on Phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 Trial Evaluating Tumor Treating Fields Therapy in Platinum-resistant Ovarian Cancer
Regulation FD disclosure · EX-99.1 to Form 8-K
Novocure Reports Second Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Novocure Announces Favorable Independent Data Monitoring Committee Recommendation to Continue Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields Therapy in Pancreatic Cancer
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K